BioLife Solutions Valuation
Is BLFS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BLFS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BLFS ($26.77) is trading below our estimate of fair value ($32.22)
Significantly Below Fair Value: BLFS is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BLFS?
Key metric: As BLFS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is BLFS's PS Ratio? | |
|---|---|
| PS Ratio | 8.4x |
| Sales | US$146.96m |
| Market Cap | US$1.21b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.2x |
| Enterprise Value/EBITDA | -43.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BLFS's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.1x | ||
TXG 10x Genomics | 2.9x | 5.8% | US$1.7b |
FTRE Fortrea Holdings | 0.6x | 2.4% | US$1.8b |
ADPT Adaptive Biotechnologies | 4.6x | 18.5% | US$692.1m |
CTKB Cytek Biosciences | 4.3x | 11.7% | US$843.7m |
BLFS BioLife Solutions | 8.4x | 11.1% | US$1.2b |
Price-To-Sales vs Peers: BLFS is expensive based on its Price-To-Sales Ratio (8.4x) compared to the peer average (3.1x).
Price to Sales Ratio vs Industry
How does BLFS's PS Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Sales vs Industry: BLFS is expensive based on its Price-To-Sales Ratio (8.4x) compared to the US Life Sciences industry average (3.2x).
Price to Sales Ratio vs Fair Ratio
What is BLFS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 8.4x |
| Fair PS Ratio | 3.1x |
Price-To-Sales vs Fair Ratio: BLFS is expensive based on its Price-To-Sales Ratio (8.4x) compared to the estimated Fair Price-To-Sales Ratio (3.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$26.77 | US$29.80 +11.3% | 4.5% | US$32.00 | US$27.00 | n/a | 10 |
| Nov ’25 | US$24.07 | US$28.90 +20.1% | 4.5% | US$30.00 | US$26.00 | n/a | 10 |
| Oct ’25 | US$24.14 | US$28.70 +18.9% | 5.4% | US$30.00 | US$26.00 | n/a | 10 |
| Sep ’25 | US$25.88 | US$27.89 +7.8% | 8.4% | US$30.00 | US$23.00 | n/a | 9 |
| Aug ’25 | US$23.36 | US$25.44 +8.9% | 12.6% | US$30.00 | US$20.00 | n/a | 9 |
| Jul ’25 | US$20.79 | US$24.78 +19.2% | 14.6% | US$30.00 | US$20.00 | n/a | 9 |
| Jun ’25 | US$21.48 | US$24.78 +15.4% | 14.6% | US$30.00 | US$20.00 | n/a | 9 |
| May ’25 | US$17.48 | US$23.13 +32.3% | 14.4% | US$30.00 | US$20.00 | n/a | 8 |
| Apr ’25 | US$17.90 | US$23.29 +30.1% | 15.2% | US$30.00 | US$20.00 | n/a | 7 |
| Mar ’25 | US$17.97 | US$23.29 +29.6% | 15.2% | US$30.00 | US$20.00 | n/a | 7 |
| Feb ’25 | US$17.97 | US$23.29 +29.6% | 15.2% | US$30.00 | US$20.00 | n/a | 7 |
| Jan ’25 | US$16.25 | US$22.14 +36.3% | 21.5% | US$30.00 | US$15.00 | n/a | 7 |
| Dec ’24 | US$13.25 | US$22.14 +67.1% | 21.5% | US$30.00 | US$15.00 | n/a | 7 |
| Nov ’24 | US$10.23 | US$23.86 +133.2% | 15.4% | US$30.00 | US$18.00 | US$24.07 | 7 |
| Oct ’24 | US$13.81 | US$25.14 +82.1% | 9.4% | US$30.00 | US$22.00 | US$24.14 | 7 |
| Sep ’24 | US$13.40 | US$25.14 +87.6% | 9.4% | US$30.00 | US$22.00 | US$25.88 | 7 |
| Aug ’24 | US$19.34 | US$30.43 +57.3% | 5.8% | US$34.00 | US$29.00 | US$23.36 | 7 |
| Jul ’24 | US$22.10 | US$30.33 +37.3% | 7.3% | US$34.00 | US$27.00 | US$20.79 | 6 |
| Jun ’24 | US$23.10 | US$30.71 +33.0% | 7.3% | US$34.00 | US$27.00 | US$21.48 | 7 |
| May ’24 | US$18.10 | US$30.71 +69.7% | 7.3% | US$34.00 | US$27.00 | US$17.48 | 7 |
| Apr ’24 | US$21.75 | US$30.86 +41.9% | 7.8% | US$34.00 | US$27.00 | US$17.90 | 7 |
| Mar ’24 | US$22.80 | US$31.00 +36.0% | 7.1% | US$34.00 | US$28.00 | US$17.97 | 7 |
| Feb ’24 | US$23.52 | US$31.00 +31.8% | 7.1% | US$34.00 | US$28.00 | US$17.97 | 7 |
| Jan ’24 | US$18.20 | US$31.50 +73.1% | 7.8% | US$35.00 | US$28.00 | US$16.25 | 8 |
| Dec ’23 | US$21.87 | US$31.50 +44.0% | 7.8% | US$35.00 | US$28.00 | US$13.25 | 8 |
| Nov ’23 | US$24.01 | US$35.75 +48.9% | 34.7% | US$68.00 | US$28.00 | US$10.23 | 8 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Spectrum Pharmaceuticals
US$209.9m
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.
SPPI
US$1.03
7D
5.3%
1Y
17.0%
Teva Pharmaceutical Industries
US$19.4b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$16.69
7D
1.2%
1Y
68.9%
IQVIA Holdings
US$36.6b
Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
IQV
US$204.02
7D
6.8%
1Y
-3.2%